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Abstract
There is a strong need to assess early tumor response to chemotherapy in order to avoid adverse effects from unnecessary
chemotherapy and allow early transition to second-line therapy. This study was to quantify tumor perfusion changes with
dynamic contrast-enhanced ultrasound (CEUS) in the evaluation of early tumor response to cytotoxic chemotherapy. Sixty
nude mice bearing with MCF-7 breast cancer were administrated with either adriamycin or sterile saline. CEUS was
performed on days 0, 2, 4 and 6 of the treatment, in which time-signal intensity (SI) curves were obtained from the
intratumoral and depth-matched liver parenchyma. Four perfusion parameters including peak enhancement (PE), area
under the curve of wash-in (WiAUC), wash-in rate (WiR) and wash-in perfusion index (WiPI) were calculated from perfusion
curves and normalized with respect to perfusion of adjacent liver parenchyma. Histopathological analysis was conducted to
evaluate tumor perfusion, tumor cell density, microvascular density (MVD) and proliferating cell density. Significant
decreases of tumor normalized perfusion parameters (i.e., nPE, nWiAUC, nWiR and nWiPI) were noticed between adriamycintreated and control groups (P,0.01) 2 days after therapy. There were significant differences of tumor volumes between
control and treated groups on day 6 (P,0.001) while there were no significant differences in tumor volume on days 0, 2 and
4 (P.0.05). Significant decreases of tumor perfusion, tumor cell density, MVD and proliferating cell density were seen in
adrianycin-treated group 2 days after therapy when compared to control group (P,0.001). Dynamic CEUS for quantification
of tumor perfusion could be used for early detection of cancer response to cytotoxic chemotherapy prior to notable tumor
shrinkage.
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based on morphologic changes, the RECIST has some disadvantages and limitations by using morphologic imaging methods.
First, the tumor morphology changes on imaging might occur
several weeks later regardless of a positive functional response to
treatment [3], which could substantially delay the judgment of
chemotherapy effectiveness. Second, conventional morphologic
imaging could not differentiate tumor necrosis or fibrosis from
residual tumor tissue [3], which could provide nonspecific
information for assessing chemotherapy. Furthermore, newly
developed chemotherapy (i.e., antiangiogenetic drugs) aims to
ablate tumor neovascularities, which requires the assessment of
tumor blood flow changes instead of tumor morphologic changes.
Thus, it is critical to develop functional imaging techniques to
better monitor tumor response to cytotoxic chemotherapy, which
overcome the limitation of current criteria based on measurement
of tumor size [1].

Introduction
Cancer treatment is a great challenge for medical research and
clinical practice. Currently, chemotherapy is still one of the most
important methods for cancer treatment, in which more than half
of all patients with malignant tumors receive chemotherapy. Due
to the fact that most of the malignant tumors are widely
heterogeneous, the response to cytotoxic chemotherapy is variable
even for the tumor with same pathologic types and differentiation
grades. Therefore, it is important to precisely assess the response to
cytotoxic therapy at its early time point, so as to reduce side effects
and unnecessary costs of ineffective therapy [1].
The criteria most commonly used to assess the effectiveness of
chemotherapy is the Response Evaluation Criteria in Solid
Tumor(RECIST)which have become widely applicable in clinical
oncological trials since it was published in 2000 [2]. Although it is
useful protocol for estimating tumor response to chemotherapy
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Functional imaging techniques such as positron-emission
tomography (PET), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), dynamic contrast-enhanced computed tomography (DCE-CT) and ultrasound (US) have been
investigated to assess tumor response to chemotherapy by
depicting the reductions in metabolic activity or the blood flow
perfusion of the tumor [4–7]. Of these, US is an attractive
modality for assessment tumor response to therapy because of the
ease with which it can be repeated without exposing the patient or
animal to any risk of radiation. Ultrasound imaging systems are
also relatively inexpensive and mobile, a particular benefit for
animal studies. Contrast-enhanced ultrasound (CEUS) offers the
major advantages of evaluating tumor perfusion in real time and
minimal invasiveness when compared to other methods for
assessment of tumor perfusion. Quantification of tumor perfusion
with CEUS has been studied to assess tumor response to
antiangiogenic therapy, and preliminary results were promising
[8–11]. Other than these molecular target drugs, currently most of
the cancer patents still undergo the treatment of cytotoxic
chemotherapy. We have previously shown that tumor blood flow
perfusion changes after cisplatin treatment with CEUS [12].
However, to the best of our knowledge, the value of quantifying
tumor blood flow perfusion with CEUS has not been tested in
early assessing tumor response to cytotoxic chemotherapy. The
purpose of this study was to determine whether CEUS can
quantitatively identify blood flow perfusion changes for the
evaluation of tumor response to a cytotoxic chemotherapeutic
drug, adriamycin, in its early stage of the treatment.

settings were adjusted at the beginning and maintained constant
during all of the experiments. For the ultrasound imaging studies,
each mouse was anesthetized by i.p. injection of pentobarbital
sodium (75 mg/kg, Sigma, USA). All ultrasound examinations
were performed by one radiologist (J.H.Z., with 7 years experience
in contrast-enhanced ultrasound), who was blind to the treatment
status. Before contrast agent injection, the greatest longitudinal,
transverse, and anteroposterior dimensions of tumors were
measured in grayscale imaging using calipers. Tumor volume
was calculated using the formula for a prolate ellipsoid:
volume = p/6 6 length 6 width 6 depth. The image plane
containing the tumor at its maximum cross section and a large
portion of the right lobe of the liver was imaged with the
transducer held manually in this position throughout the
examination.
Microbubble-based contrast agent SonoVue (Bracco, Milan,
Italy) was used for contrast-enhanced ultrasound imaging. It is
a sulfur hexafluoride gas containing agent with a phospholipids
membrane. SonoVue was dissolved with physiologic saline to 5 ml
and was injected as a bolus (0.1 ml/20 g) through the retroorbital
vein with a 27-gauge needle. The bolus injection was performed
by one radiologist (W.Z., with 5 years experience in small animals
study) within 1sec for all animals to minimize variations of
injection technique. Imaging was recorded on cine clips starting
just before the contrast agent injection and continuing for 60 sec.
For CEUS study, twenty nude mice were randomly divided into
two groups (i.e., treatment group and control group, n = 10 on
each). The 10 mice in treatment group were treated with
adriamycin (Shenzhen Main Luck Pharmaceuticals Inc., Guangdong, China) by intraperitoneal injection (4 mg/kg) once daily.
The other 10 mice in control group were received vehicle control
medium (sterile saline) with same timing and dosing schedule used
for treatment group. The time point for the first dose given was
referred to as day 0. Ultrasound imaging was performed at days 0,
2, 4 and 6 before each dosing.

Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Sun Yat-Sen University (Permit Number:
2012-A009). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

Imaging Analysis
All datasets were transferred to a commercially available
computer workstation (SonoTumor software, Bracco Research
SA, Geneva, Switzerland). A region of interest (ROI) that drawn
along the margin of the tumor and a ROI at matched depth in the
region of the right lobe of the liver parenchyma were selected by
one investigator (J.W.W., with 3 years experience in contrastenhanced ultrasound) who was blind to the treatment information
(Figure 1). The selected ROI was automatically positioned by the
software on subsequent images, with minor adjustments to correct
for respiratory motion when necessary. The analysis applies first
linearization at the pixel level to revert the effects of ‘‘log’’
compression in the ultrasound system. Results obtained from the
selected ROI represented an approximately linear depiction of the
backscattered intensity. The average of the linearized intensities of
all the pixels in the ROI was calculated to produce a time-signal
intensity curve, where the intensity is theoretically linked to
microbubble concentration [13].
Perfusion parameters of the tumor, including peak enhancement (PE), area under the curve of wash-in (WiAUC), wash-in rate
(WiR) and wash-in perfusion index (WiPI) were calculated and
normalized to those of the depth-matched liver parenchyma
(Perfusion parameters tumor/Perfusion parameters liver). The results
were noted as nPE, nWiAUC, nWiR and nWiPI (n = normalized).
PE was defined as the maximum intensity of the signal produced
by injection of the contrast agent. WiAUC was defined as the area
under the curve from staring enhancement to peak enhancement.
WiR was defined as the maximum slope between the time of onset

Cells
Human breast cancer cell line MCF-7 was obtained from the
state key laboratory of oncology in southern China. MCF-7 cells
were grown in DMEN culture medium (Hyclone Co., UT, USA)
supplemented with 10% fetal bovine serum (Gibco, NY, USA),
penicillin (50 U/mL), and streptomycin (50 mg/mL) at 37uC in
a humidified 5% CO2 atmosphere.

Animal Model
For inoculation, approximately 76107 MCF-7 cells suspended
in phosphate-buffered saline were injected subcutaneously into the
right flanks (at the level of the liver) of BALB/c nude female mice.
They were 8-week-old with body weigh from 18 to 20 g.

Imaging Protocol
Ultrasound imaging was obtained using a Sequoia 512
ultrasound unit associated with a 15L8 7.0,14.0 MHz linear
array transducer (Siemens, Mountain View, CA, USA). The probe
offers a lateral resolution of 0.35 mm and an axial resolution of
10.25 mm (both provided by the manufacturer). Coupling gel with
a gel pad was placed on the skin for stand-off scanning. Contrast
pulse sequence (CPS) imaging mode was used for evaluation of
tumor perfusion with mechanical index of 0.25, frame rate of
5 Hz, dynamic range of 78 dB, and imaging depth of 3 cm. These
PLOS ONE | www.plosone.org
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Figure 1. US image of a subcutaneous MCF7 breast cancer tumor. A, US scan showed gray-scale ultrasound image of tumor (T) adjacent to
the right lobe of the liver (L). B, CEUS shows enhancement of normal liver parenchyma and tumor. Measurements obtained from one ROI drawn on
the tumor (green ROI) and one drawn at matched depth in liver parenchyma (yellow ROI).
doi:10.1371/journal.pone.0058274.g001

were then incubated with a secondary goat antimouse antibody
(Zhongshan Goldenbridge Biology, Beijing, China). Also, Diaminobenzidine (DAB) was used for color development.
Regions with the highest tumor cell density in H&E stained
sections were located by scanning the tissue sections under 640power microscope. After identification of the regions of highest
tumor cell density, ten different fields were randomly chosen
within the regions of highest tumor cell density at 6400 powers.
The histopathologic images of each 6400 powers field were saved
as a jpeg format in the computer for the measurement of tumor
cell density as the number of nucleus in each image. Image pro
plus software was used to calculate the number of nucleus in each
image. The average of ten 400 powers field results was used for
statistical analysis.
The measurements of MVD by counting the CD34-stained
vessels under light microscopy were performed independently by
two pathologists (with 5 and 10 years MVD working experience,
respectively), who were blinded to the tumor treatment and
ultrasound findings. According to the method by Weidner et al
[15], regions with the highest vessel density (‘‘hot spots’’) were
located by scanning the tissue sections under 640-power
microscope. After identification of the ‘‘hot spots’’, three different
fields were randomly chosen within each hot spot, and each
endothelial cell or cell cluster that showed antibody staining and
that was clearly separated from adjacent clusters was counted at
6200 powers for MVD measurements. The average of the two
observers’ results was used for statistical analysis.
The proliferating cell density of the Ki-67 staining was defined
as the average number of Ki-67 staining nuclei in 10 random fields
(including periphery and centre of specimen) according to the
method described by Dowsett [16]. Ten different fields were
randomly chosen at 6400 powers and corresponding 10 pictures
were taken in each tumor slice. Again, Image pro plus software
was used to calculate the number of Ki-67 staining nuclei in each
400 powers field image. The average of ten 400 powers field results
was used for statistical analysis.

of contrast inflow and the time of peak enhancement. WiPI was
defined as area under the curve of wash-in divided by rise time.
Quality of fit was used to test the fit between the raw data and the
fitted mathematic model.

Histopathologic Analysis
A separate group of mice with MCF-7 tumors were prepared
(n = 40) and divided into control and adriamycin-treated (4 mg/
kg, i.p.) groups. Mice were treated identically to those entered into
the imaging studies above. Mice (n = 5 per time point) from the
control and treated groups were sacrificed and tumors were
excised on days 0, 2, 4 and 6. One minute before mice were
sacrificed, Hoecst 33342 (25 mg/kg in water, Sigma-Aldrich Co.,
St. Louis, MO) was injected via the retroorbital vein. Tumors were
rapidly excised and cut in half along a plane approximating to the
imaging plane. One half of each tumor was snap frozen over liquid
nitrogen for fluorescence microscopy, and one half was fixed in
10% buffered formalin before paraffin processing. Cryostat
sections (five-micrometer-thick) were cut and Hoechst 33342
labeled cells were visualized and photographed under a fluorescence microscope equipped with a camera with 365 nm excitation
and 420 nm emission filters showing blue fluorescence. Five
different high power fields (6400) were randomly chosen within
the highest fluorescence points and Image pro plus software (image
pro-plus 6.0, Media Cybernetics, Silver Spring, MD, USA) was
used to calculate the number of Hoechst 33342 labeled cells.
Hoechst 33342 is a dye that stains the nuclei of endothelial cells,
lining blood vessels that are perfused at the time of injection, and
thus affords a measure of functional tumor vasculature. The mean
number of Hoechst 33342 labeled cells reflected the blood
perfusion of tumor [14].
Four-mm-thick sections were stained with hematoxylineosin
(H&E) to assess tumor cell morphology changes. Immunohistochemical analysis was used to assess endothelial cell density
(CD34-stained) and proliferating cell density (Ki67-stained).
Antigen-retrieval procedure using citrate acid (pH of 6.0) was
performed. Following heat-induced epitope retrieval in citrate
buffer (pH of 6.0), the following primary antibodies were used,
including rat antimouse CD34 antibody (clone MEC14.7, Abcam,
UK) at 1:100 dilution and mouse anti-human Ki67 antibody
(clone MIB-1; Dako, Glostrup, Denmark) at 1:50 dilution. The
slides for evaluating CD34 expression were then incubated with
a secondary rabbit antirat antibody (Zhongshan Goldenbridge
Biology, Beijing, China) and those for evaluating Ki67 expression
PLOS ONE | www.plosone.org

Statistical Analysis
All statistical analyses were performed by SPSS version 16.0
(SPSS, Inc, Chicago, IL). Independent samples t-test was used to
analyze the significant differences of tumor volume, perfusion
parameters, tumor perfusion (Hoechst 333342 staining), tumor cell
density, proliferating cell density and MVD between the treatment
and control groups. Paired-samples t-test was used to compare the
3
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Figure 2. Changes of tumor volume and normalized perfusion parameters. A, There were significant differences of tumor volumes between
control and treated groups on days 6 (* = P,0.001) while there were no significant differences in tumor volume on days 0, 2 and 4 (P.0.05). B-E,
Changes in nPE (B), nWiAUC (C), nWiR (D) and nWiPI (E) at the different time points studied. CEUS demonstrated that all four normalized perfusion
parameters of the tumors in the control group increased on days 2, 4 and 6, while in the treatment group, all four normalized perfusion parameters of
the tumors decreased as early as 2 days after adriamycin therapy and remained low throughout the entire observation period. There were significant
differences in the four normalized perfusion parameters between control and treatment groups on day 2, 4 and 6 (* = P,0.01).
doi:10.1371/journal.pone.0058274.g002

perfusion parameters measured longitudinally by CEUS. Differences between baseline and follow-up histopathologic results were
explored with the use of the Bonferroni corrected t test. The
Pearson correlation test was used to examine the relationship
between mean changes in the perfusion parameters measured by
CEUS with tumor volume change. A p value of 0.05 or less was
considered statistically significant.

PLOS ONE | www.plosone.org

Results
Effect of Adriamycin on Tumor Growth
Before therapy, there was no significant difference in tumor
volumes between control and treatment groups (P = 0.795). The
tumor volumes in two groups increased gradually on days 2 and
4, but no significant differences were seen between two groups at
these time points (P was 0.970 and 0.275, respectively). On day
6, the tumor volume was significantly lower in the treatment

4
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Figure 3. Histopathologic analysis of tumor perfusion changes (Hoechst 333342 staining). A, The graph showed the changes of tumor
perfusion post treatment. There was significant difference in the number of Hoechst 33342 labeled cells between control and treatment groups on
days 2, 4 and 6 (* = P,0.01). B, Representative Hoechst 333342 stained sections of the control (C) and treated (T) tumors on days 0, 2, 4 and 6. Scale
bars: 50 mm.
doi:10.1371/journal.pone.0058274.g003

treatment which was 4 days earlier before the difference of tumor
sizes became measurable by conventional imaging. At day 6,
changes in the four normalized perfusion parameters measured by
CEUS well correlated with the tumor volume change (for nPE,
r = 0.702, P = 0.001; for nWiAUC, r = 0.534, P = 0.015; for nWiR,
r = 0.759, P,0.001; for nWiPI, r = 0.732, P,0.001).

group than the control group (the mean tumor volumes from
control
group = 156.44622.58 mm3,
from
treatment
group = 84.74611.59 mm3, P,0.001). These results are illustrated in Figure 2A.

Early Effect of Adriamycin on Tumor Perfusion Measured
on CEUS

Early Effect of Adriamycin on Tumor Perfusion (Hoechst
33342 Staining)

There were no significant differences in 4 normalized perfusion
parameters (i.e., nPE, nWiAUC, nWiR and nWiPI) between
control and treatment groups before treatment (P.0.05). In the
control group, CEUS demonstrated that all four normalized
perfusion parameters of the tumors significantly increased on day
2, 4 and 6 as compared with day 0 (P,0.05), while in the
treatment group, all four normalized perfusion parameters of the
tumors significantly decreased as early as 2 days after adriamycin
therapy and remained low throughout the entire observation
period as compared with day 0 (P,0.05). There were significant
differences in the four normalized perfusion parameters between
control and treatment groups on days 2, 4 and 6 (P,0.01)
(Figure 2B, 2C, 2D and 2E). It was noticed that CEUS
demonstrated a reduction of tumor perfusion 2 days after
PLOS ONE | www.plosone.org

The number of Hoechst 33342 labeled cells reflected the blood
perfusion of tumor. There was no significant difference in the
number of Hoechst 33342 labeled cells between control and
treatment groups before treatment (P = 0.578). In the control
group, Hoechst 33342 labeled cells significantly increased on day
2, 4 and 6 as compared with day 0 (P,0.001), while in the
treatment group, Hoechst 33342 labeled cells significantly decreased on day 2, 4 and 6 as compared with day 0 (P,0.001).
There was significant difference in the number of Hoechst 33342
labeled cells between control and treatment groups on days 2, 4
and 6 (P,0.01) (Figure 3).
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Figure 4. Histopathologic analysis of tumor cell density changes. A, The graph shows the changes of mean tumor cell density of the control
and treated tumors post treatment. There was significant difference in tumor cell density between control and treatment groups on days 2, 4 and 6
(* = P,.001). B, Representative photomicrographs of hemotoxylin and eosin stained sections of the control (C) and treated (T) tumors on days 0, 2, 4
and 6. Scale bars: 50 mm.
doi:10.1371/journal.pone.0058274.g004

Effect of Adriamycin on Tumor on Cell Density

Effect of Adriamycin on Tumor MVD

There was no significant difference in the tumor cell density
between control and treatment groups before treatment
(P = 0.298). In the control group, tumor cell density remained
stable on day 2, 4 and 6 as compared with day 0 (P.0.05), while in
the treatment group, tumor cell density significantly decreased on
day 2, 4 and 6 as compared with day 0 (P,0.001). There was
significant difference in tumor cell density between control and
treatment groups on days 2, 4 and 6 (P,0.001). (Figure 4).

There was no significant difference in the tumor microvascular
density (MVD) determined by immunohistochemical evaluation of
endothelial cell (CD34) density between control and treatment
groups before treatment (P = 0.635). In the control group, MVD
increased from day 0 to day 2 although not significantly difference
(P = 0.106) and then significantly increased on days 4 and 6 as
compared with day 0 (P,0.05), while in the treatment group,
MVD decreased from day 0 to day 2 although not significantly
difference (P = 0.135), and then significantly decreased on days 4
and 6 as compared with day 0 (P,0.05). There was significant
difference in MVD between control and treatment groups on days
2, 4 and 6 (P,0.001). (Figure 6).

Effect of Adriamycin on Tumor Cell Proliferating
There was no significant difference in the proliferating cell
density between control and treatment groups before treatment
(P = 0.69). In the control group, tumor proliferating cell density
remained stable on day 2, 4 and 6 as compared with day
0 (P.0.05), while in the treatment group, proliferating cell density
significantly decreased on day 2, 4 and 6 as compared with day
0 (P,0.001). There was significant difference in proliferating cell
density between control and treatment groups on days 2, 4 and 6
(P,0.01). (Figure 5).

PLOS ONE | www.plosone.org

Discussion
Therapeutic effectiveness of adriamycin was detected as early as
2 days after treatment by using CEUS imaging to quantify tumor
perfusion changes. In contrast, the measurements of the tumor
volumes after therapy were not significantly different up to 6 days,
implying that it is not feasible to assess early response to
chemotherapy by monitoring tumor dimensions, as is standard
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Figure 5. Immunohistochemical analysis of proliferating cell density changes. A, The graph shows the changes of mean proliferating cell
density of the control and treated tumors post treatment. There was significant difference in proliferating cell density between control and treatment
groups on days 2, 4 and 6 (* = P,0.001). B, Representative KI67-stained sections of the control (C) and treated (T) tumors on days 0, 2, 4 and 6. Brown
areas reflect positive staining of proliferating tumor cell. Scale bars: 50 mm.
doi:10.1371/journal.pone.0058274.g005

in most clinical surveillance of the tumor treatment using RECIST
protocol [2]. The present study demonstrated the feasibility and
possibility of quantitative CEUS technique in predicting early
response of breast cancer to cytotoxic chemotherapy in an animal
model. The preliminary results shown that the decrease in blood
perfusion of treated tumors on CEUS was associated with
reduction in tumor perfusion (Hoechst 333342 staining), tumor
cell density, proliferating cell density and MVD, as shown by both
histopathologic and immunochemistry examinations in this study.
Traditionally, clinical examination and conventional imaging
techniques, such as CT and MRI have been used to assess tumor
size and response to the treatment. However, many studies have
shown that clinical examination and conventional imaging are
inappropriate techniques since assessing the tumor size by
morphological measurement could result in over- or underestimating the tumor response to chemotherapy [17,18]. In
addition, some tumor types are not easily measured because of
their growth behavior. For example, malignant pleural mesothelioma grows as a ‘rind’ of tissue arising from the pleura rather than
by discrete nodules, so that measuring the long axis is not
appropriate [19]. Furthermore, both inter-observer and intraobserver errors often occur for a number of reasons such as poorly
PLOS ONE | www.plosone.org

defined lesions, irregular shape lesions and when imaging occurs at
different phases of contrast enhancement [1]. Therefore, it has
been well recognized that tumor size change is an imperfect
assessment method for assessing the effects of chemotherapy.
Reduction in tumor size is only a late sign of effective
chemotherapy, so that the early response of tumors to therapy is
difficult to assess using conventional radiographic modalities [20].
Early assessment of therapeutic efficacy is critical to prevent
unnecessary treatment and optimize therapeutic strategies in order
to obtain the optimal outcome of the therapy. Since it is very
important for assessing early tumor response to cytotoxic
chemotherapy, several functional imaging modalities, such as
PET), DCE-MRI and DCE-CT, are being investigated to
determine their ability to detect the tumor response in its early
stage of the treatment, and hence facilitate the tailoring of
treatment to response. PET with (18F) fluorodeoxyglucose (FDG)
is widely used for clinical staging and treatment evaluation of
cancer by depicting a reduction in the metabolic activity of the
tumor [21]. Although FDG PET has higher sensitivity than
anatomic imaging modalities, it suffers from low spatial resolution
and exposes patients to ionizing radiation (as does CT). The extent
of FDG uptake by lesions smaller than twice the quoted resolution
7
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Figure 6. Immunohistochemical analysis of tumor MVD changes. A, The graph shows the changes of mean MVD in the control and treated
tumors post treatment. There was significant difference in MVD between control and treatment groups on days 2, 4 and 6 (* = P,0.001). B,
Representative CD34-stained sections of the control (C) and treated (T) tumors on days 0, 2, 4 and 6. Brown areas reflect positive staining of
endothelial cells. Scale bars: 100 mm.
doi:10.1371/journal.pone.0058274.g006

application of ultrasound contrast agents in clinical practice,
CEUS has recently improved the US diagnostics of several
diseases, especially in the differentiation of liver lesions [31].
CEUS offers great advantages of evaluating tumor perfusion in
real time compared to other methods for assessing tumor blood
perfusion. Quantitative evaluation of tumor perfusion with CEUS
has been used to evaluate tumor response to antiangiogenic agents
which work by typically preventing the development of new blood
vessels needed to support tumor growth both in animal [8–11] and
clinical [32,33] studies, and preliminary results were promising. In
this study, the early treatment effect of a cytotoxic chemotherapeutic drug, adriamycin, was evaluated with CEUS for the first
time, and decrease in tumor perfusion was detected by CEUS in
treated tumors as early as 2 days after therapy, whereas
measurable tumor shrinkage with significance difference in the
volume was noticed 6 days after treatment, which gives a great
potential for this technique to assess early tumor response to
therapy in future preclinical and clinical studies.
The pathophysiologic basis for the tumor perfusion changes
seen in this study after chemotherapy is not yet fully understood,
but is likely to be multifactorial, relating to changes in both

of PET is often underestimated [22]. Both DCE-MRI and DCECT have shown potentials as functional imaging tools to early
assess tumor response to chemotherapy by detecting tumor blood
perfusion changes [5,23–25]. Although DCE-MRI offers relatively
good sensitivity and spatial resolution in soft tissue imaging, the
spatial resolution must be traded off to get a sufficient frame rate
for dynamic tracking of the contrast agent in order to perform
whole organ scans with functional imaging information [26].
Although DCE-CT imaging is suitable for assessment of tissue
perfusion [26], high concentration of CT contrast agent together
with the relatively high dose of radiation limit the utilization of CT
for frequent evaluation of tumor response to therapy.
Ultrasound imaging has been frequently used in clinical practice
for monitoring effects of tumor therapy. Since color and spectral
Doppler ultrasound allows semiquantitative assessment of tumor
vascularity, measurements of peak systolic velocity, end-diastolic
velocity, resistivity index and pulsatility index have shown the
potential to serve as a functional tool for monitoring tumor
response to chemotherapy [27–29]. However, the high degree of
subjectivity as well as its lack of reproducibility makes it impossible
to gain wide acceptance in clinical practice [30]. With the wide
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requirement for blood supply and microvessel changes. Adriamycin, an anthracyclinic antibiotic, is a DNA-interacting drug for
treatment of various types of cancers, such as ovarian, breast,
prostate, cervix and lung cancers. In the present study, the tumor
cell density and proliferating cell density of treated tumors was
significantly less than those of control tumors. The death of cancer
cells and inhibition of proliferating activities caused by adriamycin
induced the reduction of tumor metabolic activity, which will lead
to the decrease of tumor blood supply. On the other hand, it has
been suggested that successful chemotherapy causes cytotoxic
tumor cell death resulting in a reduction in tissue vascular
endothelial growth factor levels and hence apoptosis of immature
endothelial cells with secondary vascular shutdown [34]. Furthermore, most of the conventional chemotherapy drugs do not only
damage the tumor cells but also the endothelial cells [35], but also
contribute to the decrease of tumor perfusion. In this study, we
found that Adriamycin-treated tumors were associated with
a significant decrease of MVD as compared with control tumors.
There are some limitations in this study. First, a potential
limitation of CEUS technique is that possible variations in contrast
agent kinetics could occur through differences in the injection rate
or other injection artifacts. However, in the case of a briefly
injected 0.1 mL bolus, these variations should not lead to
a significant bias as the injection was systematically performed
by one investigator for all animals. Second, calculating tumor
perfusion in a single tumor section may have introduced a bias
since tumor tissue is inhomogenous in volume. A complete

quantification of tumor perfusion throughout the whole tumor
volume could improve the relevance of the tumor perfusion
parameters. Third, although xenografted tumors are well-accepted
and important experimental model systems, they obviously do not
mimic human tumor behavior exactly and a single cancer cell line
might not be representative of the different types of human breast
cancer. Further clinical evaluation is necessary to confirm the
validity of quantitative CEUS on early assessment of human
tumors response to chemotherapy. Finally, the use of a two-arm
study design (control vs. treatment) limits the conclusions
regarding the utility of CEUS. A better study design would be
to correlate changes in CEUS parameters of tumors with the
outcomes of individual animals.
In conclusion, this study indicates that quantitative CEUS
provided a simple way to early monitor tumor response to
cytotoxic chemotherapy by detecting tumor perfusion changes.
Dynamic CEUS for quantification of tumor perfusion could be
used for early detection of cancer response to cytotoxic chemotherapy prior to notable tumor shrinkage.
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